drugset / Trial / NCT02431845
Pharmaco(Epi)Genetic, Proteomic, and Microbiomic Study of Obsessive-Compulsive Disorder
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether pharmaco(epi)genetic study predict selective serotonin reuptake inhibitor (SSRI) responsiveness in advance before the appearance of the drug effect until 4 months(16 weeks), 6 months, and 1 year after administration of SSRIs.
Timeline
- Start
- 2013-01-01
- Primary completion
- 2030-12-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clomipramine | Small molecule | 40 mg | — |
| Subject | Clomipramine | Small molecule | 80 mg | — |
| Subject | Escitalopram | Small molecule | 40 mg | — |
| Subject | Escitalopram | Small molecule | 80 mg | — |
| Subject | Fluoxetine | Small molecule | 40 mg | — |
| Subject | Fluoxetine | Small molecule | 80 mg | — |
| Subject | Fluvoxamine | Unknown | 40 mg | — |
| Subject | Fluvoxamine | Unknown | 80 mg | — |
| Subject | Paroxetine | Small molecule | 40 mg | — |
| Subject | Paroxetine | Small molecule | 80 mg | — |
| Subject | Sertraline | Small molecule | 40 mg | — |
| Subject | Sertraline | Small molecule | 80 mg | — |